118 results on '"Hundsdörfer, Patrick"'
Search Results
2. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
3. Non-Syndromic and Syndromic Defects in Children with Extracranial Germ Cell Tumors: Data of 2610 Children Registered with the German MAKEI 96/MAHO 98 Registry Compared to the General Population
4. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations
5. Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
6. Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
7. Supplementary Figure 9 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
8. Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
9. Supplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
10. Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
11. Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
12. Supplementary Figure 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
13. Supplementary Figure 8 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
14. Supplementary Table 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
15. Supplementary Table 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
16. Supplementary Table 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
17. Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
18. Data from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
19. Supplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
20. Supplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
21. Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
22. Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
23. Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models
24. Lower incidence of grade II-IV acute Graft-versus-Host-Disease in pediatric patients recovering with high Vδ2+ T cells after allogeneic stem cell transplantation with unmanipulated bone marrow grafts: a prospective single-center cohort study.
25. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment
26. ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL
27. HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches
28. Eukaryotic Translation Initiation Factor 4GI and p97 Promote Cellular Internal Ribosome Entry Sequence-Driven Translation
29. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma
30. Supplementary Data from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma
31. Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis
32. Publisher Correction: Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
33. Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models
34. Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
35. Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics
36. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma
37. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters
38. Abstract A02: Patient-derived xenograft models of neuroblastoma as improvement for the prediction of targeted therapies for childhood cancer
39. The prothrombin 3′end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations
40. Enhancement of IRES-Mediated Translation of the c- myc and BiP mRNAs by the Poly(A) Tail Is Independent of Intact eIF4G and PABP
41. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
42. Abstract 2624: Dual PLK1 and BRD4 inhibition has synergistic therapeutic effects against high-risk rhabdomyosarcoma
43. A novel homozygous frameshift mutation in LACC1 associated with severe familial forms of juvenile idiopathic arthritis
44. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
45. Ungewöhnlicher Lebertumor bei einem 4-jährigen Mädchen
46. Bilateral Involvement Is an Independent Risk Factor in Testicular Relapse of Childhood ALL: Results of the Trials ALL-REZ BFM 83 - 2002
47. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma
48. [18F]Fluorodeoxyglucose Positron Emission Tomography for Detection of Bone Marrow Involvement in Children and Adolescents With Hodgkin's Lymphoma
49. Smac Mimetic-Mediated Sensitization Of Childhood ALL Cells For Drug-Induced Apoptosis Independent Of TNFα and NFκB Signaling Pathways
50. Retroviral transfer of themultidrug resistance‐1 gene into lineage‐committed and primitive hemopoietic cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.